ClinicalTrials.gg
Active, not recruitingNCT05413304Updated Oct 6, 2026Results posted

Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis

A Phase 1 interventional study of Pre-operative abemaciclib and Device for Cerebral Fluid Dialysate Collection in Glioma, sponsored by National Cancer Institute (NCI). Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 39 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by National Cancer Institute (NCI) · Phase 1, Interventional, and Treatment

How we know · 7 judgments

Updated Oct 6, 2026Results postedStudy documents posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
5
Allocation
Non-randomized
Ages
18 Years to 39 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 112 studies testing temozolomide in Glioma — 13 open to participants now, 18 under way, 2 of them phase 3. Temozolomide · Glioma.

Enrollment
100th of 104
5 · median 41
Started
2023
with 1 other
Phase 1
34 of 112
4 open now
Primary completion
2025-10
later than 1 of 17 live
Registered
98th of 112
by date

Among the 112 studies testing temozolomide in Glioma, this one is the 100th largest by enrollment of the 104 interventional ones that give a count, is one of 2 that started in 2023, is one of 34 in phase 1, reaches primary completion later than 1 of the 17 other live ones, and was the 98th registered.

Glioma

1,456 studies on the registry are indexed under Glioma; 351 are open to participants now.

Browse Glioma studies →

Open to participants now

13 of the 112 studies testing temozolomide in Glioma are open now, in 10 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About temozolomide

Temozolomide: first FDA approval 1999 (TEMODAR), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 267 Glioma studies recruiting now, 165 (62%) set no upper age limit and 57 (21%) stop at 75 or younger; 63 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 39 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 112 studies testing temozolomide in Glioma, or all of them as a file.
02

Study summary

Background:

Diffuse midline gliomas are the most aggressive brain tumors of childhood and young adults. Most people with these tumors survive less than 2 years. Researchers want to see if an anticancer drug (abemaciclib) can help.

Objective:

To see if researchers can measure how much abemaciclib is in a person's brain tumor and brain fluid after they take the drug for a few days.

Eligibility:

People aged 18 to 39 with recurrent high-grade glioma or diffuse midline glioma.

Design:

Participants will be screened with:

Medical history

Physical exam

Blood and urine tests

Tests of heart function

Imaging scans of the brain, with a contrast agent

Screening tests will be repeated during the study. Participants will also have chest X-rays.

Participants will take abemaciclib by mouth twice a day for 4 and a half days.

Participants will undergo surgery. They will have either a tumor biopsy (a needle will be inserted to remove a small piece of tissue) or a surgical resection (part or all of the tumor will be removed). A small tube (catheter) will be placed in their brain for 48 hours to collect fluid samples. They will have a neurological exam every few hours while the tube is in place. Two days later, the tube will be removed without surgery. Participants will stay in the hospital for about 4 days for treatment.

Based on the results of abemaciclib levels in the brain, participants may keep taking abemaciclib and another drug (temozolomide) by mouth until their cancer gets worse or they have bad side effects. While taking these two drugs, participants will come back to the clinic for follow-up routinely. They will be followed by the study for life....

Read the detailed description

Background

Diffuse midline gliomas are the most aggressive brain tumors of childhood and young adults, with documented 2-year survival rates of \<10%. These tumors are infiltrative midline high-grade gliomas. Treatment failure is due in part to the presence of the blood-brain barrier (BBB), which limits permeability of varied agents.

Efforts to evaluate drug delivery across the BBB in midline gliomas have been restricted to post biopsy specimens. In comparison, intracerebral microdialysis sampling of cortical tissue has been shown to be a highly effective tool in determining cortical neuropharmacokinetics (brain extracellular fluid penetration, accumulation and excretion) intratumorally and peritumorally in adult brain tumor participants. Microdialysis is underutilized in the adult brain tumor setting to evaluate chemotherapy or targeted therapy permeability.

Within the United States (US), midline gliomas are not routinely biopsied. However, in the last several years, using modern surgical techniques, biopsy at the time of diagnosis has been performed with acceptable risks (4% mortality rate), with a feasible means to molecularly characterize the tumors; in order to identify potentially druggable targets.

One of the main attributes of disease progression/proliferation in midline gliomas is associated with dysregulation of the cell cycle. Cyclin-dependent kinase inhibitor 2A (CDKN2A) is the primary inhibitory brake on cyclin-dependent kinase 4 and 6 (CDK4/6) driven signaling and is commonly deleted in glioblastoma, pancreas, bladder, breast and prostate cancer. The specific CDK4/6 inhibitor, abemaciclib, has Food and Drug Administration (FDA) approval for the treatment of metastatic breast cancer.

This is a safety and feasibility study to evaluate pharmacokinetic and pharmacodynamic effects post abemaciclib administration in recurrent high grade glioma participants (cortical and midline tumors). We propose a trial using clinical microdialysis, placed in diffuse midline glioma tissue post biopsy, as an experimental research tool, to assess central nervous system (CNS) drug entry and targeted inhibition with abemaciclib. These studies are focused with the overall intent to inform future clinical therapies and preclinical modeling.

Objectives:

To evaluate safety and feasibility of intratumoral microdialysis placement post high grade glioma resection or midline glioma biopsy

To evaluate safety and feasibility of brain interstitial dialysate sampling in glioma participants post abemaciclib administration

To measure intratumoral vs. systemic concentrations of abemaciclib in glioma participants post abemaciclib administration

Eligibility:

Participants must have recurrent high-grade glioma or diffuse midline glioma based on clinical and/or radiologic findings

Participants with cortical high-grade gliomas must have previous intra-operative pathology confirming disease

Participants must be =>18 and \<= 39 years of age, at time of enrollment

Ability to swallow tablets/pills

Must have adequate organ function as per laboratory testing parameters

Abemaciclib administration must be able to begin no later than 14 days after the date of radiographic diagnosis (by T2 or fluid-attenuated inversion recovery (FLAIR) imaging)

Design:

This is a safety and feasibility study to evaluate tumor pharmacokinetics (PK) and pharmacodynamics (PD) of abemaciclib in recurrent high-grade glioma and midline glioma participants in need of surgical resection or biopsy, respectively.

All participants will take abemaciclib pre-operatively for 4.5 days (9 total doses of abemaciclib) at twice daily dosing.

A maximally safe surgical resection for cortical high-grade glioma or stereotactic needle biopsy for midline glioma will be performed in the operating room (OR). Microdialysis insertion (based on participant safety and surgical feasibility) will be performed post-biopsy in the OR and placement will be verified by brain computed tomography (CT).

Continuous microdialysis sampling will be obtained over the course of the next 48 hours, with subsequent removal of the catheter at the bedside.

After discharge from National Institutes of Health (NIH) inpatient, PK and PD findings will assist in determination of whether the participant will continue to receive abemaciclib therapy. If intratumoral or PK brain dialysate sampling concentrations are >10nmol/L, or PD findings suggest cyclin-dependent kinase (CDK) inhibition (decreased expression of Retinoblastoma protein (Rb) and/or topoisomerase II (topoII), then restart of abemaciclib therapy along with temozolomide will be administered for maintenance therapy post resection or biopsy.

Maintenance therapy will be abemaciclib 150mg po twice a day (BID) x 28 days together with temozolomide 200mg/m\^2 po daily x 5 days in 28-day cycles (temozolomide 150mg/m\^2 po daily x 5 days for cycle 1). After every 3 cycles, repeat brain magnetic resonance imaging's (MRIs) will be obtained to evaluate treatment response and disease progression.

If a participant starts to exhibit signs of clinical deterioration or radiographic progression, the participant will discontinue maintenance therapy, with ongoing contact for survival approximately every 6 months (+/- 14 days) until death.

Results of the PK measurements and molecular testing will be provided to the participant's home oncologist to provide for assistance with directed therapy decisions (outside of this investigational trial).

We propose to evaluate 5 participants. The accrual ceiling will be set at 17 participants to account for screen failures and inevaluable participants.

03

Conditions studied

  • Glioma

Keywords

  • Central Nervous System
  • Cdk4/6
  • Brain Cancer
  • Surgical Resection
04

Who can participate

The criteria were revised on the registry on Oct 6, 2026. See what changed

Ages eligible
18 Years to 39 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have recurrent high-grade glioma or midline glioma based on clinical and/or radiologic findings

    • Participants with cortical high-grade gliomas must have previous intra-operative pathology confirming disease
    • Participants must be >= 18 and \<= 39 years old at the time of enrollment
    • Ability to swallow tablets/pills

Prior Therapies:

  • At least 4 weeks must have elapsed since any major surgeries, with no evidence of infections. Minimally invasive (outside of the brainstem) and central line placements are not considered major surgeries
  • Participants who have received prior treatment with abemaciclib or another specific cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor are not eligible for enrollment (ex., Ribociclib, Palbociclib - list is not all inclusive)
  • Participants who received chemotherapy must have recovered ( [CTCAE] Grade \<=1) from the acute effects of chemotherapy except for residual alopecia or Grade 2 peripheral neuropathy prior to treatment. A of at least 14 days or 4 half-lives from last disease directed therapy, whichever is shorter, is required between last chemotherapy dose and treatment.
  • Participants who received radiotherapy must have completed and fully recovered from the acute effects of radiotherapy. A washout period of at least 14 days is required between end of radiotherapy and treatment.
  • Adequate performance scale as defined below:
  • >=50% within 14 days prior to enrollment.
  • Adequate organ function within 14 days prior to enrollment as defined below:

Hematologic Function: Participants must have an >=1500/microliters, >=9 g/dL (transfusion independent, defined as not receiving blood transfusion unless related to trauma or surgeries), and >=100,000/microliters (transfusion independent, defined as not receiving platelet transfusions unless related to trauma or surgeries)

Hepatic Function: Participants must have within 1.5 x the for age, with the exception of those with Gilbert syndrome, and (AST)/alanine aminotransferase (ALT) within \< 3 x upper limit of normal.

Renal Function: Participants must have a or radioisotope (GFR) >60ml/min/1.73 m\^2 or a normal serum creatinine.

Cardiac Function: Normal (echocardiogram (ECHO) or cardiac magnetic resonance imaging (MRI) >= 53% (or the institutional normal); (QTC) or Fridericia's corrected QT (QTcF) \< 450 msec.

  • Willingness to avoid grapefruit or grapefruit juice during abemaciclib administration
  • : Ability of participant or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document.
  • Willingness of participant or LAR to sign a written informed consent document and co-enroll in study 03-N-0164
  • The effects of abemaciclib on the developing human fetus are unknown, however cyclin-dependent kinase (CDK)-inhibiting agents are known to be teratogenic. Temozolomide is a cytotoxic chemotherapeutic agent which is known to be teratogenic. For these reasons, women of must agree to use a highly effective method of prior to study entry, for the duration of study participation, and for 3 weeks after the last dose of abemaciclib and 6 months after temozolomide. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation.

    • A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a state (>= 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus).
    • Woman participants of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 7 days of the first dose of abemaciclib.

Highly effective contraception includes intrauterine devices (IUD), hormonal (birth control pills, injections, implants), tubal ligation, or partners vasectomy.

--Cases of pregnancy that occur during maternal exposures to abemaciclib should be reported. If a participant or spouse/partner is determined to be pregnant following abemaciclib initiation she must discontinue treatment immediately. Data on fetal outcomes and breastfeeding are to be collected for regulatory reporting and drug safety evaluation.

-Abemaciclib administration must be able to begin no later than 14 days after the date of radiographic diagnosis (by T2 or FLAIR imaging)

Exclusion criteria

EXCLUSION CRITERIA:

  • Participants who cannot safely undergo a due to
  • Pregnant women, or women who intent to become pregnant during the study, are excluded from this study because of the teratogenic effects of abemaciclib. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with these agents, breastfeeding should be discontinued if the mother is treated on study.
  • Serious preexisting medical condition(s) that would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest requiring oxygen therapy, severe renal impairment [e.g. estimated \<30ml/min], history of major surgical resection involving the stomach or small bowel that would preclude adequate absorption, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea).
  • Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, active bleeding diatheses or renal transplant, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest.
  • Active systemic bacterial infection (requiring intravenous [IV] antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known positivity or with known active or C [for example, hepatitis B surface antigen positive]. Participants with HIV who have adequate cluster of differentiation 4 (CD4) counts and who have no requirement for antiviral therapy will be eligible. NOTE: Screening is not required for enrollment.
  • Requires treatment with strong/moderate cytochrome P450, family 3, subfamily A. () inhibitors or inducers. Participants receiving any medications or substances that are inducers or strong/moderate inhibitors of CYP3A4 are ineligible. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently updated medical reference. As part of the enrollment/ procedures, the participant will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the participant is considering a new over-the-counter medicine or herbal product.
  • Inability to undergo MRI and/or contraindication for MRI examinations following the MRI protocol (see Study Procedure Manual). Prosthesis or orthopedic or dental braces that would interfere with MRI.
  • nausea and vomiting that would limit drug administration in the opinion of the Principal Investigator
  • Known severe to abemaciclib, temozolomide or any of abemaciclib or temozolomide or history of allergic reactions attributed to compounds of similar chemical or biologic composition to abemaciclib and temozolomide.
  • Clinical judgment by the investigator that the participant should not participate in the study
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Arm 1/Cohort 1/ Abemaciclib and Microdialysis Monitoring

    Abemaciclib orally twice a day (BID) for 4.5 days followed by resection or biopsy and microdialysis catheter placement with continuous monitoring for 48 hours post-operative and genomic sampling of tissue/blood; followed by Arm 2/abemaciclib + temozolomide maintenance therapy.

    Drug: Pre-operative abemaciclib · Device: Device for Cerebral Fluid Dialysate Collection · Device: Ashion Analytics GEM ExTra · Drug: abemaciclib + temozolomide · Drug: Temozolomide · Diagnostic Test: Brain MRI · Diagnostic Test: Brain CT · Diagnostic Test: EKG · Diagnostic Test: Chest X-ray · Procedure: Biopsy/resection

  • Experimental
    Arm 2/Cohort 2/Abemaciclib + Temozolomide Maintenance Therapy

    Maintenance therapy is abemaciclib 150mg by mouth (PO) BID x 28 days + temozolomide 200mg/m\^2 PO daily x 5 days in 28-day cycles (temozolomide 150mg/m\^2 PO daily x 5 days for cycle 1).

    Drug: Pre-operative abemaciclib · Device: Device for Cerebral Fluid Dialysate Collection · Device: Ashion Analytics GEM ExTra · Drug: abemaciclib + temozolomide · Drug: Temozolomide · Diagnostic Test: Brain MRI · Diagnostic Test: Brain CT · Diagnostic Test: EKG · Diagnostic Test: Chest X-ray · Procedure: Biopsy/resection

Interventions

  • DrugAbemaciclibStudies of AbemaciclibAbemaciclib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Pre-operatively for 4.5 days; 200mg twice daily (9 total doses)

    Also known as: Verzenio

  • DeviceDevice for Cerebral Fluid Dialysate Collection

    Post-resection or post-biopsy continuous intracerebral microdialysis sampling for 48 hours to assess central nervous system (CNS) drug entry and targeted inhibition with abemaciclib

  • DeviceAshion Analytics GEM ExTra

    Resection/biopsy genomic sampling of tumor tissue and blood to identify therapeutic targets

    Also known as: Ashion Analytics Genomic Enabled Medicine Exome and Transcriptome

  • Drugabemaciclib + temozolomide

    Drug pages: AbemaciclibStudies of AbemaciclibAbemaciclib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · TemozolomideStudies of TemozolomideTemozolomide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Abemaciclib 150mg by mouth (po) twice a day (BID) and temozolomide 200mg/m\^2 po daily x 5 days in 28-day cycles (temozolomide 150mg/m\^2 po daily x 5 days for cycle 1)

    Also known as: Verzenio + Temodar

  • Temozolomide 150mg/m\^2 by mouth (po) daily x 5 days for cycle 1

    Also known as: Temodar

  • Diagnostic testBrain MRI

    Screening (within 14 days prior to enrollment), baseline (within 14 days of first dose), as clinically indicated at catheter removal Day 7 (\>48 hours post op), maintenance therapy (after every 3 cycles), and post treatment (safety and long-term follow-up) as clinically indicated.

    Also known as: Brain magnetic resonance imaging

  • Diagnostic testBrain CT

    Microdialysis (catheter in place) Day 5 and Day 6, and as clinically indicated at catheter removal Day 7 (\>48 hours post op).

    Also known as: Brain computed tomography

  • Diagnostic testEKG

    Screening (within 14 days prior to enrollment), baseline (within 14 days of first dose), and as clinically indicated at catheter removal Day 7 (\>48 hours post op).

    Also known as: Electrocardiogram

  • Diagnostic testChest X-ray

    Baseline (within 14 days of first dose), and as clinically indicated at catheter removal Day 7 (\>48 hours post op).

    Also known as: CXR

  • ProcedureBiopsy/resection

    Microdialysis (catheter in place) Day 5 and Day 6.

    Also known as: Bx/resection

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Have Adequate Intra-tumoral Sampling Reported With an 80% Confidence Interval

    The percentage of participants who have adequate intra-tumoral sampling was determined and reported with an 80% confidence interval. Adequate intra-tumoral tissue concentration is \<10nmol/L. Intra-tumoral sampling was performed by microdialysis.

    Time frame: At surgery (less than 14 hours from surgery), biopsy (after 4 days of abemaciclib), and 2, 6, 10, 14, 18, 22, 26, 30, 34, 38,40, 44, and 48 hours post catheter insertion

  2. Percentage of Participants Who Have Adequate Intra-tumoral Sampling Reported With a 95% Confidence Interval

    The percentage of participants who have adequate intra-tumoral sampling was determined and reported with a 95% confidence interval. Adequate intra-tumoral tissue concentration is \<10nmol/L. Intra-tumoral sampling was performed by microdialysis.

    Time frame: At surgery (less than 14 hours from surgery), biopsy (after 4 days of abemaciclib), and 2, 6, 10, 14, 18, 22, 26, 30, 34, 38,40, 44, and 48 hours post catheter insertion

  3. Number of Participants Who Experience Any Type Grade 1, 2, 3, 4, and/or 5 Adverse Event (AE)/Complication Possibly, Probably, and/or Definitely Related to Adverse Events for Participants (pt) Receiving Abemaciclib

    AEs were assessed by the Common Terminology Criteria for Adverse Events v5.0. A non-serious AE is any untoward medical occurrence. A serious AE is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the pt or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 1:mild. Grade 2: moderate. Grade 3: severe. Grade 4: life-threatening. Grade 5: death related to adverse event. All participants who receive at least 1 dose of abemaciclib or undergo the procedure to place the catheter will have their safety information reported. This table is related to AEs from abemaciclib therapy(pre-surgery). Values in the table will and should be different than other AE tables based on toleration of therapy at varied times for each pt.

    Time frame: Study Day 1 through 30 days after the last intervention through study completion, an average of 4.5 months

  4. Number of Grade 1, 2, 3, 4, and/or 5 Adverse Events (AE) At Least Possibly Related Adverse Events for Participants(pt) Receiving Combination Therapy With Abemaciclib and Temozolomide

    AEs were assessed by the Common Terminology Criteria for AEs (CTCAE v5.0). A non-serious AE is any untoward medical occurrence. A serious AE is an adverse event or suspected adverse reaction that results in death, life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 1: mild. Grade 2: moderate. Grade 3: severe. Grade: 4 life-threatening. Grade 5: death related to AE. All participants who receive at least 1 dose of abemaciclib or undergo the procedure to place the catheter are reported. This table is related to AEs from abemaciclib post-surgery,given during maintenance cycle with temozolomide. Values in the table will and should be different than other AE tables based on toleration of therapy at varied times for each pt.

    Time frame: Study Day 1 through 30 days after the last intervention through study completion, an average of 4.5 months

Secondary outcomes

  1. Time to Maximum Observed Plasma Concentration an Hour (Tmax(hr) of Drug Abemaciclib

    Blood samples were collected to determine the time to maximum observed plasma concentration an hour (Tmax(hr) of drug abemaciclib. Abemaciclib levels in plasma were measured by Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS) analysis.

    Time frame: Approximately 5, 6, 10, 12, 14, 28, 52, 76 hours after last dose of abemaciclib

  2. Maximum Plasma Concentration (Cmax) of Drug Abemaciclib

    Blood samples were collected to determine the maximum plasma concentration of drug abemaciclib. Abemaciclib levels in plasma were measured by Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS) analysis.

    Time frame: Approximately 5, 6, 10, 12, 14, 28, 52, 76 hours after last dose of abemaciclib

  3. Area Under the Plasma Concentration (AUC) of Drug Abemaciclib

    AUC is a measure of the drug plasma serum concentration of abemaciclib over time. It is used to characterize drug absorption. Abemaciclib levels in plasma were measured by Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS) analysis.

    Time frame: Approximately 5, 6, 10, 12, 14, 28, 52, 76 hours after last dose of abemaciclib

  4. Maximum Plasma Concentration (Cmax) of Unbound Abemaciclib

    Unbound abemaciclib plasma exposure was calculated by the total drug exposure multiplied by the mean unbound fraction (fu,0.06) in human plasma.

    Time frame: Approximately 5, 6, 10, 12, 14, 28, 52, 76 hours after last dose of abemaciclib

  5. Area Under the Plasma Concentration (AUC) of Unbound Abemaciclib

    AUC is a measure of the total drug plasma serum concentration of abemaciclib over time. It is used to characterize drug absorption. Unbound abemaciclib plasma exposure was calculated by the total drug exposure multiplied by the mean unbound fraction (fu,0.06) in human plasma.

    Time frame: Approximately 5, 6, 10, 12, 14, 28, 52, 76 hours after last dose of abemaciclib

  6. Time to Maximum Observed Plasma Concentration an Hour (Tmax(hr) of Brain Dialysate

    Urea concentrations in blood and brain interstitial fluid were measured at timed intervals. Abemaciclib levels in plasma, brain tissue and dialysate were measured and compared by Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS) analysis to determine plasma concentration.

    Time frame: Approximately 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 40, 44, and 48 hours post catheter insertion

  7. Maximum Plasma Concentration (Cmax) of Brain Dialysate

    Blood and brain interstitial fluid were obtained via microdialysis catheter in the brain and urea (metabolite) concentrations in blood and brain interstitial fluid were measured at timed intervals. Abemaciclib levels in plasma, brain tissue and dialysate were measured by Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS) to determine plasma concentration of drug in the brain.

    Time frame: 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 40, 44, and 48 hours post catheter insertion

  8. Area Under the Plasma Concentration (AUC) of Brain Dialysate

    AUC is a measure of the total drug plasma serum concentration of abemaciclib over time. Blood and brain interstitial fluid were obtained via microdialysis catheter in the brain and urea (metabolite) concentrations in blood and brain interstitial fluid were measured at timed intervals. Abemaciclib levels in plasma, brain tissue and dialysate were measured by Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS) analysis to determine concentration of drug in the brain.

    Time frame: Approximately 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 40, 44, and 48 hours post catheter insertion

  9. Concentration of Total Drug Abemaciclib From Tissue Obtained Via Brain Biopsy

    Biopsied tumor tissue was obtained using a stereotactic needle in the brain. A minimum of 6 samples were taken and analyzed by liquid chromatography tandem mass spectrometry (LC/MS/MS) to determine drug concentrations in the brain tissue.

    Time frame: 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 40, 44, and 48 hours post catheter insertion

  10. Brain Biopsy Sampling Time

    Brain biopsy sampling time is the timing of when the tumor tissue was biopsied since the last dose of abemaciclib.

    Time frame: 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 40, 44, and 48 hours post catheter insertion

  11. Ratio of Area Under the Plasma Concentration (AUC) in Brain Dialysate to Unbound Drug Abemaciclib AUC in Plasma

    AUC is a measure of the total drug plasma serum concentration of abemaciclib over time. Unbound abemaciclib plasma exposure was calculated by the total drug exposure multiplied by the mean unbound fraction (fu,0.06) in human plasma. Abemaciclib levels in plasma, brain tissue and dialysate were measured by Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS) analysis.

    Time frame: Approximately 5, 6, 10, 12, 14, 28, 52, 76 hours after last dose of abemaciclib

Other outcomes

  1. Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)

    Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.

    Time frame: From the first study intervention, Study Day 1 through 30 days after the last abemaciclib administration, a range of every 28 ± 3 days, up to an average of 5 months.

07

Results

Posted Oct 6, 2026

Participant flow

Participant flow — Overall Study
MilestoneArm 1 Cortical High-Grade Glioma: Abemaciclib + SurgeryArm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance TherapyArm 2 Diffuse Midline Glioma: Abemaciclib + SurgeryArm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy
Started1112
Pre-op abemaciclib dosing 4.5 days1102
Resection or biopsy/microdialysis catheter placement1102
48 hours - catheter removal1102
Abemaciclib >10nmol/l or cyclin-dependent kinase (cdk) inhibition1102
Start maintenance therapy0102
Completed1102
Not completed0010
Withdrew: Withdrawal by subject0010

Outcome measures

PrimaryPercentage of Participants Who Have Adequate Intra-tumoral Sampling Reported With an 80% Confidence Interval

The percentage of participants who have adequate intra-tumoral sampling was determined and reported with an 80% confidence interval. Adequate intra-tumoral tissue concentration is \<10nmol/L. Intra-tumoral sampling was performed by microdialysis.

Time frame:
At surgery (less than 14 hours from surgery), biopsy (after 4 days of abemaciclib), and 2, 6, 10, 14, 18, 22, 26, 30, 34, 38,40, 44, and 48 hours post catheter insertion
Reported as:
Number · percentage of participants
Percentage of Participants Who Have Adequate Intra-tumoral Sampling Reported With an 80% Confidence Interval
percentage of participantsArm 1 Cortical High-Grade Glioma: Abemaciclib + SurgeryArm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance TherapyArm 2 Diffuse Midline Glioma: Abemaciclib + SurgeryArm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy
Percentage of Participants Who Have Adequate Intra-tumoral Sampling Reported With an 80% Confidence Interval100 (NA to NA)100 (NA to NA)—100 (44.7 to 100)
PrimaryPercentage of Participants Who Have Adequate Intra-tumoral Sampling Reported With a 95% Confidence Interval

The percentage of participants who have adequate intra-tumoral sampling was determined and reported with a 95% confidence interval. Adequate intra-tumoral tissue concentration is \<10nmol/L. Intra-tumoral sampling was performed by microdialysis.

Time frame:
At surgery (less than 14 hours from surgery), biopsy (after 4 days of abemaciclib), and 2, 6, 10, 14, 18, 22, 26, 30, 34, 38,40, 44, and 48 hours post catheter insertion
Reported as:
Number · percentage of participants
Percentage of Participants Who Have Adequate Intra-tumoral Sampling Reported With a 95% Confidence Interval
percentage of participantsArm 1 Cortical High-Grade Glioma: Abemaciclib + SurgeryArm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance TherapyArm 2 Diffuse Midline Glioma: Abemaciclib + SurgeryArm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy
Percentage of Participants Who Have Adequate Intra-tumoral Sampling Reported With a 95% Confidence Interval100 (NA to NA)100 (NA to NA)—100 (15.8 to 100)
PrimaryNumber of Participants Who Experience Any Type Grade 1, 2, 3, 4, and/or 5 Adverse Event (AE)/Complication Possibly, Probably, and/or Definitely Related to Adverse Events for Participants (pt) Receiving Abemaciclib

AEs were assessed by the Common Terminology Criteria for Adverse Events v5.0. A non-serious AE is any untoward medical occurrence. A serious AE is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the pt or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 1:mild. Grade 2: moderate. Grade 3: severe. Grade 4: life-threatening. Grade 5: death related to adverse event. All participants who receive at least 1 dose of abemaciclib or undergo the procedure to place the catheter will have their safety information reported. This table is related to AEs from abemaciclib therapy(pre-surgery). Values in the table will and should be different than other AE tables based on toleration of therapy at varied times for each pt.

Time frame:
Study Day 1 through 30 days after the last intervention through study completion, an average of 4.5 months
Reported as:
Count of participants · Participants
Number of Participants Who Experience Any Type Grade 1, 2, 3, 4, and/or 5 Adverse Event (AE)/Complication Possibly, Probably, and/or Definitely Related to Adverse Events for Participants (pt) Receiving Abemaciclib
ParticipantsArm 1 Cortical High-Grade Glioma: Abemaciclib + SurgeryArm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance TherapyArm 2 Diffuse Midline Glioma: Abemaciclib + SurgeryArm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy
Grade 1 Abdominal/stomach pain1001
Grade 2 Anemia1000
Grade 3 Anemia1000
Grade 1 Bilirubin increased1000
Grade 1 Constipation1000
Grade 1 Creatinine increased1001
Grade 1 Diarrhea1001
Grade 2 Dyspepsia0001
Grade 1 Fatigue1100
Grade 1 Headache1000
Grade 1 Hypokalemia0001
Grade 1 Hypophosphatemia0001
Grade 2 Insomnia0001
Grade 1 Lethargy1000
Grade 2 Lymphopenia1000
Grade 3 Lymphopenia1000
Grade 1 Nausea1100
Grade 1 Thrombocytopenia0100
Grade 1 Vomiting1000
No Grade 4 and 5 Related to Drug0000
PrimaryNumber of Grade 1, 2, 3, 4, and/or 5 Adverse Events (AE) At Least Possibly Related Adverse Events for Participants(pt) Receiving Combination Therapy With Abemaciclib and Temozolomide

AEs were assessed by the Common Terminology Criteria for AEs (CTCAE v5.0). A non-serious AE is any untoward medical occurrence. A serious AE is an adverse event or suspected adverse reaction that results in death, life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 1: mild. Grade 2: moderate. Grade 3: severe. Grade: 4 life-threatening. Grade 5: death related to AE. All participants who receive at least 1 dose of abemaciclib or undergo the procedure to place the catheter are reported. This table is related to AEs from abemaciclib post-surgery,given during maintenance cycle with temozolomide. Values in the table will and should be different than other AE tables based on toleration of therapy at varied times for each pt.

Time frame:
Study Day 1 through 30 days after the last intervention through study completion, an average of 4.5 months
Reported as:
Number · adverse events
Number of Grade 1, 2, 3, 4, and/or 5 Adverse Events (AE) At Least Possibly Related Adverse Events for Participants(pt) Receiving Combination Therapy With Abemaciclib and Temozolomide
adverse eventsArm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance TherapyArm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy
Grade 1 Anemia01
Grade 1 Creatinine increased01
Grade 1 Diarrhea01
Grade 1 Dyspepsia10
Grade 2 Dyspepsia01
Grade 1 Fatigue10
Grade 2 Lymphopenia01
Grade 3 Lymphopenia01
Grade 1 Myalgia10
Grade 1 Nausea11
Grade 1 Neutrophil decreased10
Grade 2 Neutrophil decreased11
Grade 1 WBC decreased10
Grade 2 WBC decreased11
Grade 1 Scalp pain01
No Grade 4 and 5 Related to Drug00
SecondaryTime to Maximum Observed Plasma Concentration an Hour (Tmax(hr) of Drug Abemaciclib

Blood samples were collected to determine the time to maximum observed plasma concentration an hour (Tmax(hr) of drug abemaciclib. Abemaciclib levels in plasma were measured by Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS) analysis.

Time frame:
Approximately 5, 6, 10, 12, 14, 28, 52, 76 hours after last dose of abemaciclib
Reported as:
Median · hr
Time to Maximum Observed Plasma Concentration an Hour (Tmax(hr) of Drug Abemaciclib
hrArm 1 Cortical High-Grade Glioma: Abemaciclib + SurgeryArm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance TherapyArm 2 Diffuse Midline Glioma: Abemaciclib + SurgeryArm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy
Time to Maximum Observed Plasma Concentration an Hour (Tmax(hr) of Drug Abemaciclib7.02 ± 3.760.38 ± 3.76—8.05 ± 3.76
SecondaryMaximum Plasma Concentration (Cmax) of Drug Abemaciclib

Blood samples were collected to determine the maximum plasma concentration of drug abemaciclib. Abemaciclib levels in plasma were measured by Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS) analysis.

Time frame:
Approximately 5, 6, 10, 12, 14, 28, 52, 76 hours after last dose of abemaciclib
Reported as:
Median · nM
Maximum Plasma Concentration (Cmax) of Drug Abemaciclib
nMArm 1 Cortical High-Grade Glioma: Abemaciclib + SurgeryArm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance TherapyArm 2 Diffuse Midline Glioma: Abemaciclib + SurgeryArm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy
Maximum Plasma Concentration (Cmax) of Drug Abemaciclib378.2 ± 40.34360 ± 40.34—323.25 ± 40.34
SecondaryArea Under the Plasma Concentration (AUC) of Drug Abemaciclib

AUC is a measure of the drug plasma serum concentration of abemaciclib over time. It is used to characterize drug absorption. Abemaciclib levels in plasma were measured by Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS) analysis.

Time frame:
Approximately 5, 6, 10, 12, 14, 28, 52, 76 hours after last dose of abemaciclib
Reported as:
Median · hr*nM
Area Under the Plasma Concentration (AUC) of Drug Abemaciclib
hr*nMArm 1 Cortical High-Grade Glioma: Abemaciclib + SurgeryArm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance TherapyArm 2 Diffuse Midline Glioma: Abemaciclib + SurgeryArm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy
Area Under the Plasma Concentration (AUC) of Drug Abemaciclib9018.9 ± 723.710153.8 ± 723.7—9413.3 ± 723.7
SecondaryMaximum Plasma Concentration (Cmax) of Unbound Abemaciclib

Unbound abemaciclib plasma exposure was calculated by the total drug exposure multiplied by the mean unbound fraction (fu,0.06) in human plasma.

Time frame:
Approximately 5, 6, 10, 12, 14, 28, 52, 76 hours after last dose of abemaciclib
Reported as:
Mean · nM
Maximum Plasma Concentration (Cmax) of Unbound Abemaciclib
nMArm 1 Cortical High-Grade Glioma: Abemaciclib + SurgeryArm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance TherapyArm 2 Diffuse Midline Glioma: Abemaciclib + SurgeryArm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy
Maximum Plasma Concentration (Cmax) of Unbound Abemaciclib22.69 ± 2.4221.6 ± 2.42—19.39 ± 2.42
SecondaryArea Under the Plasma Concentration (AUC) of Unbound Abemaciclib

AUC is a measure of the total drug plasma serum concentration of abemaciclib over time. It is used to characterize drug absorption. Unbound abemaciclib plasma exposure was calculated by the total drug exposure multiplied by the mean unbound fraction (fu,0.06) in human plasma.

Time frame:
Approximately 5, 6, 10, 12, 14, 28, 52, 76 hours after last dose of abemaciclib
Reported as:
Mean · hr*nM
Area Under the Plasma Concentration (AUC) of Unbound Abemaciclib
hr*nMArm 1 Cortical High-Grade Glioma: Abemaciclib + SurgeryArm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance TherapyArm 2 Diffuse Midline Glioma: Abemaciclib + SurgeryArm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy
Area Under the Plasma Concentration (AUC) of Unbound Abemaciclib541.13 ± 43.42609.23 ± 43.42—564.8 ± 43.42
SecondaryTime to Maximum Observed Plasma Concentration an Hour (Tmax(hr) of Brain Dialysate

Urea concentrations in blood and brain interstitial fluid were measured at timed intervals. Abemaciclib levels in plasma, brain tissue and dialysate were measured and compared by Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS) analysis to determine plasma concentration.

Time frame:
Approximately 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 40, 44, and 48 hours post catheter insertion
Reported as:
Mean · hr
Time to Maximum Observed Plasma Concentration an Hour (Tmax(hr) of Brain Dialysate
hrArm 1 Cortical High-Grade Glioma: Abemaciclib + SurgeryArm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance TherapyArm 2 Diffuse Midline Glioma: Abemaciclib + SurgeryArm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy
Time to Maximum Observed Plasma Concentration an Hour (Tmax(hr) of Brain Dialysate7.0 ± 2.2811.0 ± 2.28—10.9 ± 2.28
SecondaryMaximum Plasma Concentration (Cmax) of Brain Dialysate

Blood and brain interstitial fluid were obtained via microdialysis catheter in the brain and urea (metabolite) concentrations in blood and brain interstitial fluid were measured at timed intervals. Abemaciclib levels in plasma, brain tissue and dialysate were measured by Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS) to determine plasma concentration of drug in the brain.

Time frame:
2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 40, 44, and 48 hours post catheter insertion
Reported as:
Median · nM
Maximum Plasma Concentration (Cmax) of Brain Dialysate
nMArm 1 Cortical High-Grade Glioma: Abemaciclib + SurgeryArm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance TherapyArm 2 Diffuse Midline Glioma: Abemaciclib + SurgeryArm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy
Maximum Plasma Concentration (Cmax) of Brain Dialysate7.5 ± 53.7219.1 ± 53.72—105.8 ± 53.72
SecondaryArea Under the Plasma Concentration (AUC) of Brain Dialysate

AUC is a measure of the total drug plasma serum concentration of abemaciclib over time. Blood and brain interstitial fluid were obtained via microdialysis catheter in the brain and urea (metabolite) concentrations in blood and brain interstitial fluid were measured at timed intervals. Abemaciclib levels in plasma, brain tissue and dialysate were measured by Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS) analysis to determine concentration of drug in the brain.

Time frame:
Approximately 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 40, 44, and 48 hours post catheter insertion
Reported as:
Median · hr*nM
Area Under the Plasma Concentration (AUC) of Brain Dialysate
hr*nMArm 1 Cortical High-Grade Glioma: Abemaciclib + SurgeryArm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance TherapyArm 2 Diffuse Midline Glioma: Abemaciclib + SurgeryArm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy
Area Under the Plasma Concentration (AUC) of Brain Dialysate148.2 ± 673.48440.30 ± 673.48—1433.0 ± 673.48
SecondaryConcentration of Total Drug Abemaciclib From Tissue Obtained Via Brain Biopsy

Biopsied tumor tissue was obtained using a stereotactic needle in the brain. A minimum of 6 samples were taken and analyzed by liquid chromatography tandem mass spectrometry (LC/MS/MS) to determine drug concentrations in the brain tissue.

Time frame:
2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 40, 44, and 48 hours post catheter insertion
Reported as:
Median · nM
Concentration of Total Drug Abemaciclib From Tissue Obtained Via Brain Biopsy
nMArm 1 Cortical High-Grade Glioma: Abemaciclib + SurgeryArm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance TherapyArm 2 Diffuse Midline Glioma: Abemaciclib + SurgeryArm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy
Concentration of Total Drug Abemaciclib From Tissue Obtained Via Brain Biopsy3387.77 ± 1296.822202.0 ± 1296.82—1343.0 ± 1296.82
SecondaryBrain Biopsy Sampling Time

Brain biopsy sampling time is the timing of when the tumor tissue was biopsied since the last dose of abemaciclib.

Time frame:
2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 40, 44, and 48 hours post catheter insertion
Reported as:
Mean · hr
Brain Biopsy Sampling Time
hrArm 1 Cortical High-Grade Glioma: Abemaciclib + SurgeryArm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance TherapyArm 2 Diffuse Midline Glioma: Abemaciclib + SurgeryArm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy
Brain Biopsy Sampling Time6.67 (0 to 48)5.24 (0 to 48)—4.33 (0 to 48)
SecondaryRatio of Area Under the Plasma Concentration (AUC) in Brain Dialysate to Unbound Drug Abemaciclib AUC in Plasma

AUC is a measure of the total drug plasma serum concentration of abemaciclib over time. Unbound abemaciclib plasma exposure was calculated by the total drug exposure multiplied by the mean unbound fraction (fu,0.06) in human plasma. Abemaciclib levels in plasma, brain tissue and dialysate were measured by Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS) analysis.

Time frame:
Approximately 5, 6, 10, 12, 14, 28, 52, 76 hours after last dose of abemaciclib
Reported as:
Median · Ratio
Ratio of Area Under the Plasma Concentration (AUC) in Brain Dialysate to Unbound Drug Abemaciclib AUC in Plasma
RatioArm 1 Cortical High-Grade Glioma: Abemaciclib + SurgeryArm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance TherapyArm 2 Diffuse Midline Glioma: Abemaciclib + SurgeryArm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy
Ratio of Area Under the Plasma Concentration (AUC) in Brain Dialysate to Unbound Drug Abemaciclib AUC in Plasma0.27 ± 1.310.72 ± 1.31—2.73 ± 1.31
Other pre-specifiedNumber of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)

Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.

Time frame:
From the first study intervention, Study Day 1 through 30 days after the last abemaciclib administration, a range of every 28 ± 3 days, up to an average of 5 months.
Reported as:
Count of participants · Participants
Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)
ParticipantsArm 1 Cortical High-Grade Glioma: Abemaciclib + SurgeryArm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance TherapyArm 2 Diffuse Midline Glioma: Abemaciclib + SurgeryArm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy
Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)1102

Adverse events

Collected over All-Cause Mortality and Adverse Events were monitored/assessed from the first study intervention, Study Day 1 through 30 days after the last abemaciclib administration, a range of every 28 ± 3 days, up to an average of 5 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery1/1 (100%)1/1 (100%)1/1 (100%)
Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy0/1 (0%)1/1 (100%)1/1 (100%)
Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery———
Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy1/2 (50%)1/2 (50%)2/2 (100%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
EventArm 1 Cortical High-Grade Glioma: Abemaciclib + SurgeryArm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance TherapyArm 2 Diffuse Midline Glioma: Abemaciclib + SurgeryArm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy
Abdominal painGastrointestinal disorders1/10/1—0/2
AnemiaBlood and lymphatic system disorders1/10/1—0/2
AnxietyPsychiatric disorders1/10/1—0/2
Blood and lymphatic system disorders - Other, specify: Fe def.Blood and lymphatic system disorders1/10/1—0/2
ConstipationGastrointestinal disorders1/10/1—0/2
DiarrheaGastrointestinal disorders1/11/1—0/2
Disease progressionGeneral disorders1/10/1—0/2
DyspepsiaGastrointestinal disorders0/11/1—0/2
DysphasiaNervous system disorders1/10/1—0/2
Facial muscle weaknessNervous system disorders1/10/1—0/2
Most frequent other events
Showing 10 of 65
Most frequent other events
EventArm 1 Cortical High-Grade Glioma: Abemaciclib + SurgeryArm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance TherapyArm 2 Diffuse Midline Glioma: Abemaciclib + SurgeryArm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy
AlopeciaMetabolism and nutrition disorders0/11/1—0/2
AnemiaBlood and lymphatic system disorders1/10/1—1/2
AnorexiaMetabolism and nutrition disorders1/11/1—0/2
Blood bicarbonate decreasedInvestigations1/10/1—0/2
Blood bilirubin increasedInvestigations1/10/1—0/2
BruisingInjury, poisoning and procedural complications0/11/1—0/2
ConstipationGastrointestinal disorders0/11/1—1/2
Creatinine increasedInvestigations1/10/1—1/2
DepressionPsychiatric disorders0/11/1—0/2
Dry skinSkin and subcutaneous tissue disorders0/11/1—0/2

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Arm 1 Cortical High-Grade Glioma: Abemaciclib + SurgeryArm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance TherapyArm 2 Diffuse Midline Glioma: Abemaciclib + SurgeryArm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance TherapyTotal
<=18 years00000
Between 18 and 65 years11125
>=65 years00000
Age, Continuous
Age, Continuous(years)Arm 1 Cortical High-Grade Glioma: Abemaciclib + SurgeryArm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance TherapyArm 2 Diffuse Midline Glioma: Abemaciclib + SurgeryArm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance TherapyTotal
Mean28222728.5 ± 9.1926.8 ± 5.36
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1 Cortical High-Grade Glioma: Abemaciclib + SurgeryArm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance TherapyArm 2 Diffuse Midline Glioma: Abemaciclib + SurgeryArm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance TherapyTotal
Female10012
Male01113
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm 1 Cortical High-Grade Glioma: Abemaciclib + SurgeryArm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance TherapyArm 2 Diffuse Midline Glioma: Abemaciclib + SurgeryArm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance TherapyTotal
Hispanic or Latino00000
Not Hispanic or Latino11013
Unknown or Not Reported00112
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm 1 Cortical High-Grade Glioma: Abemaciclib + SurgeryArm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance TherapyArm 2 Diffuse Midline Glioma: Abemaciclib + SurgeryArm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance TherapyTotal
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White11114
More than one race00000
Unknown or Not Reported00011
Region of Enrollment
Region of Enrollment(participants)Arm 1 Cortical High-Grade Glioma: Abemaciclib + SurgeryArm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance TherapyArm 2 Diffuse Midline Glioma: Abemaciclib + SurgeryArm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance TherapyTotal
United States11125
Tumor Type
Tumor Type(Participants)Arm 1 Cortical High-Grade Glioma: Abemaciclib + SurgeryArm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance TherapyArm 2 Diffuse Midline Glioma: Abemaciclib + SurgeryArm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance TherapyTotal
Astrocytoma, isocitrate dehydrogenase (IDH) mutant01001
Diffuse hemispheric glioma, glycine to arginine/valine at codon 34 (G34)- mutant10113
Diffuse midline glioma, histone H3 lysine 27 (H3K27)-altered00011
Previous Lines of Treatment
Previous Lines of Treatment(Participants)Arm 1 Cortical High-Grade Glioma: Abemaciclib + SurgeryArm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance TherapyArm 2 Diffuse Midline Glioma: Abemaciclib + SurgeryArm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance TherapyTotal
110001
201102
300022
08

Study locations

1 site
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
09

References and documents

Publications

  • Nduom EK, Glod J, Brown DA, Fagan M, Dalmage M, Heiss J, Steinberg SM, Peer C, Figg WD, Jackson S. Clinical protocol: Feasibility of evaluating abemaciclib neuropharmacokinetics of diffuse midline glioma using intratumoral microdialysis. PLoS One. 2023 Sep 8;18(9):e0291068. doi: 10.1371/journal.pone.0291068. eCollection 2023. PubMed 37682953 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All individual participant data (IPD) recorded in the medical record will be shared with intramural investigators upon request. In addition, all large-scale genomic sequencing data will be shared with subscribers to the database of Genotypes and Phenotypes (dbGaP).

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Clinical data available during the study and indefinitely. Genomic data will be shared from the time of upload to the database of Genotypes and Phenotypes (dbGaP).

Access criteria: Clinical data will be made available via subscription to Biomedical Translational Research Information System (BTRIS) and with the permission of the study principal investigator (PI). Requests for all collected IPD data from clinical trials, conducted under a binding collaborative agreement between National Cancer Institute (NCI)/Division of Cancer Treatment and Diagnosis (DCTD) and a pharmaceutical/biotechnology company, that are not under Data and Safety Monitoring Board (DSMB) monitoring must be in compliance with the terms of the binding collaborative agreement and must be approved by NCI/DCTD and the Pharmaceutical Collaborator (i.e., the NCI Experimental Therapeutics Clinical Trials Network (ETCTN) Director in conjunction with the NCI/DCTD Regulatory Affairs Branch). Genomic individual participant data (IPD) will be shared through the database of Genotypes and Phenotypes (dbGaP) per rules of the database, for purposes of genomic analysis.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Oct 2025, 30 months.

Results were first posted in Oct 2026, 11 months after primary completion.

Of 166 non-industry phase 1 interventional studies under Glioma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 87. This study's 30 months is below that.

Counting every sponsor, half of 213 studies reached it within 59 months; a quarter within 36 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2022
First posted
Jun 10, 2022
StartActual
Apr 7, 2023
Primary completionActual
Oct 21, 2025
CompletionEst.
Sep 1, 2027
Results first posted
Oct 6, 2026
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 6, 2026
Enrollment
1→5
Oct 6, 2026
Eligibility
8 inclusion criteria edited; 3 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedParticipants must have recurrent high -grade glioma or midline glioma based on clinical and/or radiologic findings
  • EditedParticipants with cortical high -grade gliomas must have previous intra-operative pathology confirming disease
  • EditedParticipants who have received prior treatment with abemaciclib or another specific cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor are not eligible for enrollment (ex., Ribociclib, Palbociclib - list is not all inclusive)
  • EditedHepatic Function: Participants must have bilirubin within 1.5 x the upper limit of normal for age, with the exception of those with Gilbert syndrome, and aspartate aminotransferase (AST)/alanine aminotransferase (ALT) within < 3 x upper limit of normal.
  • EditedRenal Function: Participants must have a creatinine clearance or radioisotope glomerular filtration rate (GFR) >60ml/min/1.73 m2m\^2 or a normal serum creatinine.
  • EditedCardiac Function: Normal ejection fraction (echocardiogram (ECHO) or cardiac magnetic resonance imaging (MRI) >= 53% (or the institutional normal); Corrected QT (QTC) or Fridericia's corrected QT (QTcF) < 450 msec.
  • EditedThe effects of abemaciclib on the developing human fetus are unknown, however cyclin-dependent kinase (CDK)-inhibiting agents are known to be teratogenic. Temozolomide is a cytotoxic chemotherapeutic agent which is known to be teratogenic. For these reasons, women of child-bearing potential must agree to use a highly effective method of contraception prior to study entry, for the duration of study participation, and for 3 weeks after the last dose of abemaciclib and 6 months after temozolomide. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation.
  • EditedHighly effective contraception includeincludes intrauterine devices (IUD), hormonal (birth control pills, injections, implants), tubal ligation, or partner spartners vasectomy .
Exclusion criteria
  • EditedSerious preexisting medical condition(s) that would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest requiring oxygen therapy, severe renal impairment [e.g. estimated creatinine clearance <30ml/min], history of major surgical resection involving the stomach or small bowel that would preclude adequate absorption, or preexisting Crohn 's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea).
  • EditedActive systemic bacterial infection (requiring intravenous [IV] antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C [for example, hepatitis B surface antigen positive]. Participants with HIV who have adequate cluster of differentiation 4 (CD4) counts and who have no requirement for antiviral therapy will be eligible. NOTE: Screening is not required for enrollment.
  • EditedRequires treatment with strong/moderate cytochrome P450, family 3, subfamily A. (CYP3A) inhibitors or inducers. Participants receiving any medications or substances that are inducers or strong/moderate inhibitors of CYP3A4 are ineligible. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently- updated medical reference. As part of the enrollment/informed consent procedures, the participant will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the participant is considering a new over-the-counter medicine or herbal product.
Oct 6, 2026
Interventions
Added Drug: Temozolomide·Diagnostic test: Brain MRI·Diagnostic test: Brain CT·Diagnostic test: EKG·Diagnostic test: Chest X-ray·and 1 more
All 6

Drug: Temozolomide · Diagnostic test: Brain MRI · Diagnostic test: Brain CT · Diagnostic test: EKG · Diagnostic test: Chest X-ray · Procedure: Biopsy/resection

. Arm changed 1/Abemaciclib and microdialysis monitoring→Arm 1/Cohort 1/ Abemaciclib and Microdialysis Monitoring. Arms added: Arm 2/Cohort 2/Abemaciclib + Temozolomide Maintenance Therapy
Oct 6, 2026
Primary outcomes
4 added, 3 removed
What changed in the outcomes
  • AddedPercentage of Participants Who Have Adequate Intra-tumoral Sampling Reported With an 80% Confidence IntervalTime frame: At surgery (less than 14 hours from surgery), biopsy (after 4 days of abemaciclib), and 2, 6, 10, 14, 18, 22, 26, 30, 34, 38,40, 44, and 48 hours post catheter insertion
  • AddedPercentage of Participants Who Have Adequate Intra-tumoral Sampling Reported With a 95% Confidence IntervalTime frame: At surgery (less than 14 hours from surgery), biopsy (after 4 days of abemaciclib), and 2, 6, 10, 14, 18, 22, 26, 30, 34, 38,40, 44, and 48 hours post catheter insertion
  • AddedNumber of Participants Who Experience Any Type Grade 1, 2, 3, 4, and/or 5 Adverse Event (AE)/Complication Possibly, Probably, and/or Definitely Related to Adverse Events for Participants (pt) Receiving AbemaciclibTime frame: Study Day 1 through 30 days after the last intervention through study completion, an average of 4.5 months
  • AddedNumber of Grade 1, 2, 3, 4, and/or 5 Adverse Events (AE) At Least Possibly Related Adverse Events for Participants(pt) Receiving Combination Therapy With Abemaciclib and TemozolomideTime frame: Study Day 1 through 30 days after the last intervention through study completion, an average of 4.5 months
  • Removedintra-tumoral sampling adequacyTime frame: surgery/biopsy and multiple timed retrievals 2 - 48 hours post catheter insertion
  • Removedconcentration of abemaciclibTime frame: intratumoral: surgery/biopsy and multiple timed retrievals 2 - 48 hours post catheter insertion; blood/systemic: surgery/biopsy, multiple timed retrievals 1-72 hours post catheter insertion, and Day 5 of every other maintenance therapy cycle
  • Removedadverse eventsTime frame: Study Day 1 through 30 days after the last intervention
Oct 6, 2026
Secondary outcomes
12 added, 1 removed
What changed in the outcomes
  • AddedTime to Maximum Observed Plasma Concentration an Hour (Tmax(hr) of Drug AbemaciclibTime frame: Approximately 5, 6, 10, 12, 14, 28, 52, 76 hours after last dose of abemaciclib
  • AddedMaximum Plasma Concentration (Cmax) of Drug AbemaciclibTime frame: Approximately 5, 6, 10, 12, 14, 28, 52, 76 hours after last dose of abemaciclib
  • AddedArea Under the Plasma Concentration (AUC) of Drug AbemaciclibTime frame: Approximately 5, 6, 10, 12, 14, 28, 52, 76 hours after last dose of abemaciclib
  • AddedMaximum Plasma Concentration (Cmax) of Unbound AbemaciclibTime frame: Approximately 5, 6, 10, 12, 14, 28, 52, 76 hours after last dose of abemaciclib
  • AddedArea Under the Plasma Concentration (AUC) of Unbound AbemaciclibTime frame: Approximately 5, 6, 10, 12, 14, 28, 52, 76 hours after last dose of abemaciclib
  • AddedTime to Maximum Observed Plasma Concentration an Hour (Tmax(hr) of Brain DialysateTime frame: Approximately 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 40, 44, and 48 hours post catheter insertion
  • AddedMaximum Plasma Concentration (Cmax) of Brain DialysateTime frame: 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 40, 44, and 48 hours post catheter insertion
  • AddedArea Under the Plasma Concentration (AUC) of Brain DialysateTime frame: Approximately 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 40, 44, and 48 hours post catheter insertion
  • AddedConcentration of Total Drug Abemaciclib From Tissue Obtained Via Brain BiopsyTime frame: 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 40, 44, and 48 hours post catheter insertion
  • AddedBrain Biopsy Sampling TimeTime frame: 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 40, 44, and 48 hours post catheter insertion
  • AddedRatio of Area Under the Plasma Concentration (AUC) in Brain Dialysate to Unbound Drug Abemaciclib AUC in PlasmaTime frame: Approximately 5, 6, 10, 12, 14, 28, 52, 76 hours after last dose of abemaciclib
  • Removedrelationship between abemaciclib PK and PD studies on subsequent treatment and participant outcomeTime frame: 10 years post-enrollment
  • Addedother outcomeNumber of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)Time frame: From the first study intervention, Study Day 1 through 30 days after the last abemaciclib administration, a range of every 28 ± 3 days, up to an average of 5 months.
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Results posted
    Enrollment 1→5
    Eligibility 8 inclusion criteria edited; 3 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedParticipants must have recurrent high -grade glioma or midline glioma based on clinical and/or radiologic findings
    • EditedParticipants with cortical high -grade gliomas must have previous intra-operative pathology confirming disease
    • EditedParticipants who have received prior treatment with abemaciclib or another specific cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor are not eligible for enrollment (ex., Ribociclib, Palbociclib - list is not all inclusive)
    • EditedHepatic Function: Participants must have bilirubin within 1.5 x the upper limit of normal for age, with the exception of those with Gilbert syndrome, and aspartate aminotransferase (AST)/alanine aminotransferase (ALT) within < 3 x upper limit of normal.
    • EditedRenal Function: Participants must have a creatinine clearance or radioisotope glomerular filtration rate (GFR) >60ml/min/1.73 m2m\^2 or a normal serum creatinine.
    • EditedCardiac Function: Normal ejection fraction (echocardiogram (ECHO) or cardiac magnetic resonance imaging (MRI) >= 53% (or the institutional normal); Corrected QT (QTC) or Fridericia's corrected QT (QTcF) < 450 msec.
    • EditedThe effects of abemaciclib on the developing human fetus are unknown, however cyclin-dependent kinase (CDK)-inhibiting agents are known to be teratogenic. Temozolomide is a cytotoxic chemotherapeutic agent which is known to be teratogenic. For these reasons, women of child-bearing potential must agree to use a highly effective method of contraception prior to study entry, for the duration of study participation, and for 3 weeks after the last dose of abemaciclib and 6 months after temozolomide. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation.
    • EditedHighly effective contraception includeincludes intrauterine devices (IUD), hormonal (birth control pills, injections, implants), tubal ligation, or partner spartners vasectomy .
    Exclusion criteria
    • EditedSerious preexisting medical condition(s) that would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest requiring oxygen therapy, severe renal impairment [e.g. estimated creatinine clearance <30ml/min], history of major surgical resection involving the stomach or small bowel that would preclude adequate absorption, or preexisting Crohn 's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea).
    • EditedActive systemic bacterial infection (requiring intravenous [IV] antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C [for example, hepatitis B surface antigen positive]. Participants with HIV who have adequate cluster of differentiation 4 (CD4) counts and who have no requirement for antiviral therapy will be eligible. NOTE: Screening is not required for enrollment.
    • EditedRequires treatment with strong/moderate cytochrome P450, family 3, subfamily A. (CYP3A) inhibitors or inducers. Participants receiving any medications or substances that are inducers or strong/moderate inhibitors of CYP3A4 are ineligible. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently- updated medical reference. As part of the enrollment/informed consent procedures, the participant will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the participant is considering a new over-the-counter medicine or herbal product.
    Primary outcomes 4 added, 3 removed
    What changed in the outcomes
    • AddedPercentage of Participants Who Have Adequate Intra-tumoral Sampling Reported With an 80% Confidence IntervalTime frame: At surgery (less than 14 hours from surgery), biopsy (after 4 days of abemaciclib), and 2, 6, 10, 14, 18, 22, 26, 30, 34, 38,40, 44, and 48 hours post catheter insertion
    • AddedPercentage of Participants Who Have Adequate Intra-tumoral Sampling Reported With a 95% Confidence IntervalTime frame: At surgery (less than 14 hours from surgery), biopsy (after 4 days of abemaciclib), and 2, 6, 10, 14, 18, 22, 26, 30, 34, 38,40, 44, and 48 hours post catheter insertion
    • AddedNumber of Participants Who Experience Any Type Grade 1, 2, 3, 4, and/or 5 Adverse Event (AE)/Complication Possibly, Probably, and/or Definitely Related to Adverse Events for Participants (pt) Receiving AbemaciclibTime frame: Study Day 1 through 30 days after the last intervention through study completion, an average of 4.5 months
    • AddedNumber of Grade 1, 2, 3, 4, and/or 5 Adverse Events (AE) At Least Possibly Related Adverse Events for Participants(pt) Receiving Combination Therapy With Abemaciclib and TemozolomideTime frame: Study Day 1 through 30 days after the last intervention through study completion, an average of 4.5 months
    • Removedintra-tumoral sampling adequacyTime frame: surgery/biopsy and multiple timed retrievals 2 - 48 hours post catheter insertion
    • Removedconcentration of abemaciclibTime frame: intratumoral: surgery/biopsy and multiple timed retrievals 2 - 48 hours post catheter insertion; blood/systemic: surgery/biopsy, multiple timed retrievals 1-72 hours post catheter insertion, and Day 5 of every other maintenance therapy cycle
    • Removedadverse eventsTime frame: Study Day 1 through 30 days after the last intervention
    Secondary outcomes 12 added, 1 removed
    What changed in the outcomes
    • AddedTime to Maximum Observed Plasma Concentration an Hour (Tmax(hr) of Drug AbemaciclibTime frame: Approximately 5, 6, 10, 12, 14, 28, 52, 76 hours after last dose of abemaciclib
    • AddedMaximum Plasma Concentration (Cmax) of Drug AbemaciclibTime frame: Approximately 5, 6, 10, 12, 14, 28, 52, 76 hours after last dose of abemaciclib
    • AddedArea Under the Plasma Concentration (AUC) of Drug AbemaciclibTime frame: Approximately 5, 6, 10, 12, 14, 28, 52, 76 hours after last dose of abemaciclib
    • AddedMaximum Plasma Concentration (Cmax) of Unbound AbemaciclibTime frame: Approximately 5, 6, 10, 12, 14, 28, 52, 76 hours after last dose of abemaciclib
    • AddedArea Under the Plasma Concentration (AUC) of Unbound AbemaciclibTime frame: Approximately 5, 6, 10, 12, 14, 28, 52, 76 hours after last dose of abemaciclib
    • AddedTime to Maximum Observed Plasma Concentration an Hour (Tmax(hr) of Brain DialysateTime frame: Approximately 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 40, 44, and 48 hours post catheter insertion
    • AddedMaximum Plasma Concentration (Cmax) of Brain DialysateTime frame: 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 40, 44, and 48 hours post catheter insertion
    • AddedArea Under the Plasma Concentration (AUC) of Brain DialysateTime frame: Approximately 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 40, 44, and 48 hours post catheter insertion
    • AddedConcentration of Total Drug Abemaciclib From Tissue Obtained Via Brain BiopsyTime frame: 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 40, 44, and 48 hours post catheter insertion
    • AddedBrain Biopsy Sampling TimeTime frame: 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 40, 44, and 48 hours post catheter insertion
    • AddedRatio of Area Under the Plasma Concentration (AUC) in Brain Dialysate to Unbound Drug Abemaciclib AUC in PlasmaTime frame: Approximately 5, 6, 10, 12, 14, 28, 52, 76 hours after last dose of abemaciclib
    • Removedrelationship between abemaciclib PK and PD studies on subsequent treatment and participant outcomeTime frame: 10 years post-enrollment
    • Addedother outcomeNumber of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)Time frame: From the first study intervention, Study Day 1 through 30 days after the last abemaciclib administration, a range of every 28 ± 3 days, up to an average of 5 months.
    Interventions Added Drug: Temozolomide·Diagnostic test: Brain MRI·Diagnostic test: Brain CT·Diagnostic test: EKG·Diagnostic test: Chest X-ray·and 1 more
    All 6

    Drug: Temozolomide · Diagnostic test: Brain MRI · Diagnostic test: Brain CT · Diagnostic test: EKG · Diagnostic test: Chest X-ray · Procedure: Biopsy/resection

    . Arm changed 1/Abemaciclib and microdialysis monitoring→Arm 1/Cohort 1/ Abemaciclib and Microdialysis Monitoring. Arms added: Arm 2/Cohort 2/Abemaciclib + Temozolomide Maintenance Therapy
    + 8 other changes: verification date, responsible party, oversight details, description, design details, data sharing statement, index terms and registry notes

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05413304
Responsible party
Sadhana Jackson (Principal Investigator, National Cancer Institute (NCI)) — Principal investigator
First posted
Jun 10, 2022
Start date
Apr 7, 2023
Primary completion
Oct 21, 2025
Completion
Sep 1, 2027 (estimated)
Results posted
Oct 6, 2026
Last update
Oct 6, 2026

Study contacts

Sadhana Jackson, M.D.
principal investigator · National Cancer Institute (NCI)

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Abemaciclib · Temozolomide

Start the discussion